DOCSLIB.ORG

A Phase I Trial of a Single High Dose of Idarubicin Combined With

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Phase I Trial of a Single High Dose of Idarubicin Combined With Leukemia (1998) 12, 865–868 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 http://www.stockton-press.co.uk/leu A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia MA Weiss, P Drullinsky, P Maslak, D Scheinberg and DW Golde Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Cornell University Medical College, New York, NY, USA Relapsed or refractory adult acute lymphoblastic leukemia single large dose based on the long half-life of its active (ALL) carries a grave prognosis. The most promising strategy metabolite idarubicinol. We therefore conducted a phase I for curing these patients is through re-induction chemotherapy followed by successful allogeneic transplant. We studied a new dose escalation study of a single dose of idarubicin combined high-dose induction regimen inorder to improve the outcome with high-dose cytarabine to determine the MTD of idarubicin for these patients. Eighteen adult patients with relapsed/ when given in this regimen. refractory ALL were treated on a phase I study of high-dose cytarabine combined with a single escalating dose of idarub- icin. Five patients had primary refractory disease and 13 were Materials and methods .treated in refractory relapse. Nine patients (50%) had Ph؉ ALL The induction regimen was cytarabine 3 g/m2/day intravenously days 1–5 and idarubicin as a single intravenous dose on day Trial design 3. G-CSF 5 ␮g/kg subcutaneously every 12 h was started on day 7. The initial idarubicin dose was 20 mg/m2 with dose escal- Between January 1994 and August 1996, 18 previously ations of 10 mg m2. Cohorts of three patients were treated at treated adult patients with the diagnoses of ALL (17 patients) each idarubicin dose level. Unacceptable toxicity was encoun- or lymphoblastic lymphoma (one patient) were entered on this tered at 50 mg/m2 with one death from infection and one death from cardiotoxicity in a patient with significant prior anthracyc- study. Patients were between 18 and 60 years of age with a line exposure. There were no instances of grade 4 non-hematol- diagnosis of relapsed or refractory ALL or lymphoblastic lym- ogic toxicity encountered at idarubicin doses of 20 mg/m2, phoma. The induction regimen consisted of cytarabine (Ara- 30 mg/m2, or 40 mg/m2. The data suggest a dose–response C) 3.0 g/m2/day intravenously over 3 h on days 1–5. Idarub- relationship for increasing doses of idarubicin with 0/3 com- icin was administered as a single dose on day 3. Three 2 2 plete responses (CR) at 20 mg/m , 1/3 CR at 30 mg/m , and 7/12 patients were accrued to each dose level. If there was one (58%) CR at idarubicin doses у40 mg/m2. We conclude that concomitant administration of cytarabine 3 g/m2/day × 5 and occurrence of grade 4 non-hematologic toxicity at a particular high-dose idarubicin at 40 mg/m2 as a single dose on day 3 can dose level, three additional patients were accrued at that dose be administered safely to patients with refractory and level. Two patients experiencing grade 4 non-hematologic relapsed ALL. toxicity closed accrual to that dose level and defined the pre- Keywords: relapsed refractory adult ALL; cytarabine; idarubicin ceding dose as the phase II dose. Patients were treated at ida- rubicin dose levels of 20 mg/m2, 30 mg/m2, 40 mg/m2, and 50 mg/m2. Patients achieving a CR received consolidation Introduction therapy with methotrexate 1000 mg/m2 intravenously by 3 h infusion and mercaptopurine 250 mg/m2 orally every 6 h for Curent chemotherapy induction regimens result in complete four doses (total dose 1000 mg/m2) and leucovorin 15 mg/m2 remission for 65–85% of adult patients with acute lympho- every 6 h for nine doses starting 24 h after methotrexate was blastic leukemia (ALL).1–11 There is a significant relapse rate, administered. Consolidation therapy was administered 7–14 however, and only 20–30% of all patients will be cured of days after the patient was discharged from the hospital follow- their disease.1–11 Therefore the majority of adults with ALL will ing induction therapy and was repeated again 14 days later. require therapy for relapsed or refractory disease. Patients with suitable HLA-identical donors were rec- Traditionally, salvage regimens have relied on combi- ommended for allogeneic transplant. Other patients, upon nations of vincristine, prednisone and additional agents which completion of consolidation who continued in CR, proceeded reiterate initial induction strategies.12,13 More recently, ther- to an autologous transplant. The protocol and consent form apy for relapsed and refractory patients has focused on high- were approved by the Institutional Review Board of Memorial dose cytarabine containing regimens. High-dose cytarabine as Hospital. Written informed consent was obtained from all a single agent can produce responses in approximately 30% patients. of relapsed/refractory patients.14 In combination with L-aspar- aginase,15–17 doxorubicin,18 idarubicin,19,20 or mitoxan- trone,21–23 complete responses in as many as 59% of patients Evaluation criteria have been reported. Experience at our institution and else- where with cytarabine and a single high dose of mitoxantrone The diagnosis of ALL (or lymphoblastic lymphoma) was based indicates that the combination is quite active in adult ALL.1,24 on morphologic evaluation of the bone marrow aspirate (or Idarubicin is a particularly interesting drug to administer as a lymph node biopsy). In addition, histochemical, immuno- phenotypic and cytogenetic analyses were performed as adjunctive studies. Chromosome preparations were obtained Correspondence: M Weiss, Memorial Sloan-Kettering Cancer Center, according to conventional methods following short-term cul- 1275 York Avenue, New York, NY 10021, USA; Fax: 212 772 8441 ture. Metaphase preparations were stained to reveal Giemsa Received 12 September 1997; accepted 25 November 1997 and/or quinacrine banding patterns. Cytarabine and high-dose idarubicin in adult ALL MA Weiss et al 866 Table 1 Patient characteristics toxicity. There were no instances of grade 4 non-hematologic toxicity encountered at idarubicin dose levels of 20 mg/m2, Male:Female 13:5 30 mg/m2, or 40 mg/m2. At 50 mg/m2 two of the four patients Median age (range) 32 (20–56) treated died from complications of therapy. One patient who Median duration of prior therapy in had previously received substantial prior anthracycline months (range) 12 (5–36) 2 Prior therapy with cytarabine 18 (doxorubicin 120 mg/m ) and anthracenedione (mitoxantrone Ph+ ALL 9 80 mg/m2) therapy died of congestive heart failure 66 days after receiving high-dose idarubicin. This patient had achieved a CR to this regimen prior to the cardiac death. The second patient to die at the 50 mg/m2 dose level developed progres- Patients were classified as relapsed, primary refractory, or sive pneumonia while pancytopenic and died of uncontrolled refractory relapse, based on their response to prior therapy. Patients who relapsed while not on active therapy were classi- infection on day 31 of therapy. This patient died with a hypo- fied as ‘relapsed’. Patients who never achieved a CR despite cellular bone marrow without evidence of leukemia. These at least one standard course of induction therapy were con- two patients experiencing grade 4 non-hematologic toxicity closed accrual to this dose level and defined 40 mg/m2 as the sidered to be ‘primary refractory’. Patients who relapsed while MTD for this trial. receiving chemotherapy or those who relapsed and did not achieve a second CR to a standard re-induction regimen were classified as in ‘refractory relapse’. A complete response was defined as the disappearance of Response all clinical evidence of leukemia for a minimum of 4 weeks. Eight patients (44%) achieved a complete response. There The patient had to have a neutrophil count greater than 2 1000/␮l, a platelet count greater than 100 000/␮l, no circulat- were no complete reponses seen at the idarubicin 20 mg/m dose level, one CR in three patients treated at idarubicin ing blasts, and a normal bone marrow differential (less than 2 5% blasts) in a qualitatively normal or hypercellular bone 30 mg/m , five CRs in eight patients treated at idarubicin 40 mg/m2, and two of four patients treated at 50 mg/m2 achie- marrow. ved a CR. Patients treated below the MTD had a complete Patients not achieving a CR were considered failures and removed from study. The survival of patients was measured response rate of 17% compared with 58% for patients treated from the initiation of the protocol therapy. Duration of com- at the MTD or higher. Median duration of response was brief plete response was measured from the initial CR until docu- at 2 months (range 1–4 months) with duration of CR ‘censor- ed’ at the time of transplant. Five of these patients ultimately mentation of relapse. Toxicity was graded according to the underwent an allogeneic or autologous transplant. Two National Cancer Institute common toxicity criteria.25 patients who achieved a CR had early relapse and were unable to undergo planned transplant. One patient offered an Results autologous transplant refused this procedure and relapsed 4 months later. Four patients underwent allogeneic bone mar- Patient characteristics row transplant. Three expired from transplant-related compli- cations while in complete remission and one patient remains A total of 18 patients were treated on this protocol (Table 1). alive and in remission 13 months post transplant. One patient There were 13 men and five women. The median age was 32 underwent autologous transplant in CR but relapsed 2 months with a range of 20–56 years.
Load more

Recommended publications
  • Idamycin PFS® Idarubicin Hydrochloride Injection
    Idamycin PFS® idarubicin hydrochloride injection Rx only FOR INTRAVENOUS USE ONLY WARNINGS 1. IDAMYCIN PFS Injection should be given slowly into a freely flowing intravenous infusion. It must never be given intramuscularly or subcutaneously. Severe local tissue necrosis can occur if there is extravasation during administration. 2. As is the case with other anthracyclines the use of IDAMYCIN PFS can cause myocardial toxicity leading to congestive heart failure. Cardiac toxicity is more common in patients who have received prior anthracyclines or who have pre- existing cardiac disease. 3. As is usual with antileukemic agents, severe myelosuppression occurs when IDAMYCIN PFS is used at effective therapeutic doses. 4. It is recommended that IDAMYCIN PFS be administered only under the supervision of a physician who is experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection. 5. Dosage should be reduced in patients with impaired hepatic or renal function. (See DOSAGE AND ADMINISTRATION.) DESCRIPTION IDAMYCIN PFS Injection contains idarubicin hydrochloride and is a sterile, semi- synthetic, preservative-free solution (PFS) antineoplastic anthracycline for intravenous use. Chemically, idarubicin hydrochloride is 5, 12-Naphthacenedione, 9-acetyl-7-[(3- amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11- trihydroxyhydrochloride, (7S-cis). The structural formula is as follows: C26 H27 NO9 .HCL M.W. 533.96 1 Reference ID: 3668307 IDAMYCIN PFS is a sterile, red-orange, isotonic parenteral preservative-free solution, available in 5 mL (5 mg), 10 mL (10 mg) and 20 mL (20 mg) single-use-only vials.
    [Show full text]
  • Idarubicin.Pdf
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrIDARUBICIN idarubicin hydrochloride injection Preservative Free Solution, 1 mg/mL, intravenous injection Antineoplastic Agent Pfizer Canada ULC Date of Initial Authorization: 17,300 Trans-Canada Highway July 30, 2013 Kirkland, Quebec, H9J 2M5 Date of Revision: September 14, 2021 Submission Control Number: 255782 ©Pfizer Canada ULC, 2021 IDARUBICIN (idarubicin hydrochloride injection) Page 1 of 31 RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions, Cardiovascular JA/2021 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ..........................................................................................2 TABLE OF CONTENTS ............................................................................................................2 1 INDICATIONS.............................................................................................................4 1.1 Pediatrics .................................................................................................................4 1.2 Geriatrics..................................................................................................................4 2 CONTRAINDICATIONS................................................................................................4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ...........................................................5 4 DOSAGE AND ADMINISTRATION................................................................................5
    [Show full text]
  • Summary Attachment for Eudract
    Avenue E. Mounier 83/11 1200 Brussels Belgium Tel: +32 2 774 1611 Email: [email protected] www.eortc.org Summary Attachment for EudraCT Name of Individual study Table Referring to Part of the Dossier (For National Authority Use Sponsor/Company: Only) EORTC Name of the Volume: finished product Name of Active Page Ingredients: Clofarabine Cytarabine Idarubicin Title of the Study Clofarabine in combination with a standard remissioninduction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS) : a phase I-II study of the EORTC-LG and GIMEMA (AML-14A trial) Investigators & Study Centers Number of Country City patients Belgium 4 101.Hopital Jules Bordet (BE) Brussels 1 109.A.Z. St Jan (BE) Brugge 3 Italy 28 3931.Tor Vergata Roma (IT) Roma 12 733.La Sapienza Ematologia (IT) Roma 16 Netherlands 43 304.RU Nijmegen (NL) Nijmegen 24 310.Univ Med Ctr Leiden (NL) Leiden 13 22.J Bosch 'S Hertogenb (NL) 's-Hertogenbosch 6 Grand Total 75 ST-006-AF-01 Page 1 of 4 Template version 2 Short Study Report for Health Authorities EORTC Name of Individual study Table Referring to Part of the Dossier (For National Authority Use Sponsor/Company: Only) EORTC Name of the Volume: finished product Name of Active Page Ingredients: Clofarabine Cytarabine Idarubicin Publication Willemze R, Suciu S, Muus P, Halkes CJ, Meloni G, Meert L, Karrasch M, Rapion J, (reference) Vignetti M, Amadori S, de Witte T, Marie JP.Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • How I Treat How I Treat Hyperleukocytosis in Acute Myeloid Leukemia
    From www.bloodjournal.org by guest on January 2, 2016. For personal use only. How I Treat How I treat hyperleukocytosis in acute myeloid leukemia Christoph R¨olligand Gerhard Ehninger Medizinische Klinik und Poliklinik I, Universit¨atsklinikumder Technischen Universit¨at Dresden, Germany Hyperleukocytosis (HL) per se is a labora- chronic leukemias, and particularly leuko- lactate dehydrogenase as an indicator for tory abnormality, commonly defined by stasis occurs more often in acute myeloid high proliferation are part of prognostic a white blood cell count >100 000/mL, leukemia (AML) for several reasons. Only scores guiding risk-adapted consolidation caused by leukemic cell proliferation. Not a small proportion of AML patients present strategies, HL at initial diagnosis must be the high blood count itself, but complica- with HL, but these patients have a partic- considered a hematologic emergency and tions such as leukostasis, tumor lysis syn- ularly dismal prognosis because of (1) a requires rapid action of the admitting drome, and disseminated intravascular higher risk of early death resulting from physician in order to prevent early death. coagulation put the patient at risk and HL complications; and (2) a higher proba- (Blood. 2015;125(21):3246-3252) require therapeutic intervention. The risk bility of relapse and death in the long run. of complications is higher in acute than in Whereas initial high blood counts and high Incidence and pathophysiology In untreated acute myeloid leukemia (AML), ;5% to 20% of patients factor VII.18 TLS may occur as a result of spontaneous or treatment- present with hyperleukocytosis (HL).1-10 In a patient with HL, under- induced cell death.
    [Show full text]
  • Acute Lymphoblastic Leukemia (ALL) (Part 1 Of
    LEUKEMIA TREATMENT REGIMENS: Acute Lymphoblastic Leukemia (ALL) (Part 1 of 12) Note: The National Comprehensive Cancer Network (NCCN) Guidelines® for Acute Lymphoblastic Leukemia (ALL) should be consulted for the management of patients with lymphoblastic lymphoma. Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. They are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any
    [Show full text]
  • (Idarubicin) with Pharmacokinetic and in Vitro Drug Sensitivity Testing in Children with Refractory Leukemia1
    (CANCER RESEARCH 48, 5348-5352. September 15. 1988] Phase I Clinical Trial of Orally Administered 4-Demethoxydaunorubicin (Idarubicin) with Pharmacokinetic and in Vitro Drug Sensitivity Testing in Children with Refractory Leukemia1 Ching-Hon Pui,2 Siebold S. N. de Graaf,3 Lois W. Dow, John H. Rodman, William E. Evans, Bruce S. Alpert, and Sharon B. Murphy Departments ofHematology and Oncology [C-H. P., L. W. D., S. B. M.] and Pharmaceutical Division [S. S. N. d. G., J. H. R., W. E. E.], St. Jude Children's Research Hospital, and Divisions of Hematology-Oncology [C-H. P., L. W. D., S. B. M.] and Cardiology [B. S. A.], Department of Pediatrics, University of Tennessee, Memphis, College of Medicine, Memphis, Tennessee 38101 ABSTRACT than that of analogues or i.v. idarubicin (9, 16). However, nausea and vomiting were generally more severe in patients Fifteen children with acute leukemia in relapse, refractory to conven receiving oral idarubicin (16). As a single agent in adults, oral tional therapy, were treated with idarubicin administered orally for 3 consecutive days in dosages ranging from 30 to 50 mg/m2 per day at 19- idarubicin has antileukemic activity at dosages of 45 to 90 mg/ m2 distributed over 3 consecutive days (9, 17, 18). Very little to 21-day intervals. Gastrointestinal complications, including nausea, vomiting, abdominal pain, diarrhea and stomatitis, were the major forms information is available for oral idarubicin treatment in children of dose-limiting toxicity, affecting the majority of patients at all levels of with leukemia. We report here the results of Phase I clinical, idarubicin dosage.
    [Show full text]
  • S4 Acute Myeloid Leukaemia
    Haematology Cancer Clinical Guidelines Haematology Expert Advisory Group (EAG) on behalf of Northern Cancer Alliance Title: Haematology Cancer Clinical Guidelines Authors: Haematology EAG Circulation List: As detailed on page 2 Contact Details: Mrs C McNeill, Senior Administrator, Cancer Alliance Telephone: 01138252976 Version History: Date: 10.04.18 Version: V17-section 4 Review Date: November 2019 Document Control Version Date Summary Review Date V17 Date Agreed: Haematology EAG members agreed the Guidelines on: Emailed to group on 12.04.18, for formal endorsement at the next meeting. Review Date: November 2019 1 CONTENTS SECTION 1 NEHODS- Northern England Haemato- Diagnostic Service SECTION 2 Guidelines for Cytogenetic analysis in Haematological Malignancies SECTION 3 North of England Cancer Network Guidelines and Indications for PETCT SECTION 4 Guidelines for management of Acute Myeloid Leukaemia (AML) SECTION 5 Guidelines for Management of Myelodysplastic Syndromes SECTION 6 Guidelines for Management of Acute Lymphoblastic Leukaemia SECTION 7 Guidelines for the Management of Chronic Myeloid Leukaemia SECTION 8 Guidelines for Management of Myeloproliferative Disorders Polycythaemia Vera (PRV) Myelofibrosis (MF) SECTION 9 Guidelines for Management of Chronic Lymphocytic Leukaemia (CLL) and Lymphoproliferative Disorders Hairy Cell Leukaemia T-Prolymphocytic Leukaemia Waldenstrom Macroglobulinaemia SECTION 10 Guidelines for the Management of Low-grade Non-Hodgkin Lymphoma Mantle Cell Lymphoma SECTION 11 Guidelines for the Management
    [Show full text]
  • CYTOTOXIC and NON-CYTOTOXIC HAZARDOUS MEDICATIONS
    CYTOTOXIC and NON-CYTOTOXIC HAZARDOUS MEDICATIONS1 CYTOTOXIC HAZARDOUS MEDICATIONS NON-CYTOTOXIC HAZARDOUS MEDICATIONS Altretamine IDArubicin Acitretin Iloprost Amsacrine Ifosfamide Aldesleukin Imatinib 3 Arsenic Irinotecan Alitretinoin Interferons Asparaginase Lenalidomide Anastrazole 3 ISOtretinoin azaCITIDine Lomustine Ambrisentan Leflunomide 3 azaTHIOprine 3 Mechlorethamine Bacillus Calmette Guerin 2 Letrozole 3 Bleomycin Melphalan (bladder instillation only) Leuprolide Bortezomib Mercaptopurine Bexarotene Megestrol 3 Busulfan 3 Methotrexate Bicalutamide 3 Methacholine Capecitabine 3 MitoMYcin Bosentan MethylTESTOSTERone CARBOplatin MitoXANtrone Buserelin Mifepristone Carmustine Nelarabine Cetrorelix Misoprostol Chlorambucil Oxaliplatin Choriogonadotropin alfa Mitotane CISplatin PACLitaxel Cidofovir Mycophenolate mofetil Cladribine Pegasparaginase ClomiPHENE Nafarelin Clofarabine PEMEtrexed Colchicine 3 Nilutamide 3 Cyclophosphamide Pentostatin cycloSPORINE Oxandrolone 3 Cytarabine Procarbazine3 Cyproterone Pentamidine (Aerosol only) Dacarbazine Raltitrexed Dienestrol Podofilox DACTINomycin SORAfenib Dinoprostone 3 Podophyllum resin DAUNOrubicin Streptozocin Dutasteride Raloxifene 3 Dexrazoxane SUNItinib Erlotinib 3 Ribavirin DOCEtaxel Temozolomide Everolimus Sirolimus DOXOrubicin Temsirolimus Exemestane 3 Tacrolimus Epirubicin Teniposide Finasteride 3 Tamoxifen 3 Estramustine Thalidomide Fluoxymesterone 3 Testosterone Etoposide Thioguanine Flutamide 3 Tretinoin Floxuridine Thiotepa Foscarnet Trifluridine Flucytosine Topotecan Fulvestrant
    [Show full text]
  • Acute Myeloid Leukemia (AML) Treatment Regimens
    Acute Myeloid Leukemia (AML) Treatment Regimens Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. uInduction Therapy1 Note: All recommendations are Category 2A unless otherwise indicated. The NCCN believes the best option for any patient with cancer is in a clinical trial and strongly encourages this option for all patients. PATIENT CRITERIA REGIMEN AND DOSING Age <60 years2-8 Days 1–3: An anthracycline (daunorubicin 60–90mg/m2 IV OR idarubicin 12mg/m2) Days 1–7: Cytarabine 100–200mg/m2 continuous IV (Category 1).
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?
    cells Review Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments? Jan Philipp Bewersdorf and Amer M. Zeidan * Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, PO Box 208028, New Haven, CT 06520-8028, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-203-737-7103; Fax: +1-203-785-7232 Received: 19 September 2020; Accepted: 15 October 2020; Published: 17 October 2020 Abstract: Up to 18% of patients with acute myeloid leukemia (AML) present with a white blood cell (WBC) count of greater than 100,000/µL, a condition that is frequently referred to as hyperleukocytosis. Hyperleukocytosis has been associated with an adverse prognosis and a higher incidence of life-threatening complications such as leukostasis, disseminated intravascular coagulation (DIC), and tumor lysis syndrome (TLS). The molecular processes underlying hyperleukocytosis have not been fully elucidated yet. However, the interactions between leukemic blasts and endothelial cells leading to leukostasis and DIC as well as the processes in the bone marrow microenvironment leading to the massive entry of leukemic blasts into the peripheral blood are becoming increasingly understood. Leukemic blasts interact with endothelial cells via cell adhesion molecules such as various members of the selectin family which are upregulated via inflammatory cytokines released by leukemic blasts. Besides their role in the development of leukostasis, cell adhesion molecules have also been implicated in leukemic stem cell survival and chemotherapy resistance and can be therapeutically targeted with specific inhibitors such as plerixafor or GMI-1271 (uproleselan).
    [Show full text]